Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers (DELOGAST)

Individual and Socio-economic Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers

This study evaluates the role of socioeconomic and individual factors in the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) in oeso-gastric cancer.

Study Overview

• Status: Completed
• Conditions: Gastric Adenocarcinoma; Oesophageal Carcinoma
• Intervention / Treatment: Other: Questionnaire

Detailed Description

Reducing the time between the onset of the first symptoms of cancer and the first consultation with a doctor (patient delay) is essential to improve the vital prognosis and quality of life of patients. Recent data suggest that some sociocognitive and emotional determinants may explain patient delay from a complementary point of view. The main objective of this study is to assess whether, in oeso-gastric cancer, patient delay is linked to these sociocognitive and emotional factors, in addition to previously known factors.

We intend to include in this study 300 patients with a not yet treated oeso-gastric cancer diagnosed in one of 10 health centres in the North of France region. The collected data will be analysed to underline the differences between patients who consulted a doctor earlier versus those who consulted later with a cut off at 8 weeks.

• Study Type: Interventional
• Enrollment (Actual): 258
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Boulogne-sur-Mer, France
    • Centre Hospitalier de Boulogne Sur Mer
  • Béthune, France
    • Centre Hospitalier de Béthune
  • Calais, France
    • Centre hospitalier de Calais
  • Dechy, France
    • Centre Leonard de Vinci
  • Dunkirk, France
    • Centre d 'oncologie Dunkerquois
  • Lille, France
    • Centre Oscar Lambret
  • Lille, France, 59037
    • CHRU, Hôpital Claude Huriez
  • Roubaix, France
    • Centre Hospitalier de Roubaix
  • Seclin, France
    • Centre Hospitalier de Seclin
  • Valenciennes, France
    • Centre hospitalier de valenciennes

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• age ≥ 18 years
• oesophageal, oeso-gastric junction or gastric cancer non treated cancer
• patient informed of his diagnosis
• speak fluent french

Exclusion Criteria:

• history of cancer
• psychological history
• patient under guardianship-
• fortuitous diagnosis of cancer

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Questionnaire; Auto and hetero questionnaire	Other: Questionnaire; Auto and hetero questionnaires: STAI Y B, State-Trait Anxiety Inventoriage; Brief COPE; RHHI-24, Revised Health Hardiness Inventory; IPQ-R, Illness Perception Questionnaire

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time limit of first doctor consultation	Median time between date of symptoms appearance and date of first consultation	baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time limit of system of care	Median time between date of he beginning of clinical investigations and the beginning of treatment	baseline
cTNM Stage	Stage TNM by distinguishing the early stages (I, II) vs. (III, IV)	baseline
clinical variables (i.e medical history, symptoms, entry into care pathway)	clinical variables associated with time of first doctor consultation	baseline
Socio-cognitive variables	Socio-cognitive variables associated with time of first doctor consultation	baseline
Emotional variables	Emotional variables associated with time of first doctor consultation	baseline
Survival		At 3 years

Collaborators and Investigators

• Sponsor: University Hospital, Lille
• Collaborators: University of Lille Nord de France
• Investigators: Principal Investigator: Guillaume Piessen, MD, PhD, University Hospital, Lille

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2017
• Primary Completion (Actual): February 7, 2025
• Study Completion (Actual): February 7, 2025

Study Registration Dates

• First Submitted: August 8, 2017
• First Submitted That Met QC Criteria: August 8, 2017
• First Posted (Actual): August 11, 2017

Study Record Updates

• Last Update Posted (Estimated): December 23, 2025
• Last Update Submitted That Met QC Criteria: December 16, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Head and Neck Neoplasms; Esophageal Diseases; Esophageal Neoplasms; Health Care Quality, Access, and Evaluation; Investigative Techniques; Epidemiologic Methods; Data Collection; Health Care Evaluation Mechanisms; Quality of Health Care; Public Health; Environment and Public Health; Surveys and Questionnaires
• Other Study ID Numbers: 2015_74; 2015-A01986-43 (Other Identifier: ID-RCB number, ANSM)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No